Revelol AM 25/5mg Tablet (Amlodipine/Metoprolol Succinate)

Description

Revelol AM 25/5mg Tablet (Amlodipine/Metoprolol Succinate) — Complete Clinical and Patient Information Guide

Product Overview

Revelol AM 25/5mg Tablet (Amlodipine/Metoprolol Succinate) contains Amlodipine 5mg + Metoprolol Succinate 25mg as its active pharmaceutical ingredient, belonging to the long-acting dihydropyridine CCB + cardioselective beta-1 blocker fixed-dose combination. It is clinically indicated for hypertension — particularly where both vasodilatory CCB and rate-slowing/cardiac-protecting beta-blockade are clinically indicated; stable angina with hypertension. This guide has been prepared in accordance with YMYL (Your Money Your Life) content standards, drawing on regulatory prescribing information, peer-reviewed pharmacological literature, and established clinical guidelines.

Revelol AM 25/5 combines amlodipine and Metoprolol Succinate in a fixed-dose tablet providing complementary CCB vasodilation and beta-blocker cardiac protection for hypertension management with improved adherence compared to separate tablets.

About Revelol AM 25/5 and Its Active Ingredient

Amlodipine 5mg + Metoprolol Succinate 25mg is the pharmacologically active compound in Revelol AM 25/5, a well-established cardiovascular or therapeutic agent with a clinical evidence base developed across decades of research. All cardiovascular and hormonal pharmacotherapy requires physician supervision — drug interactions, contraindications, and dose optimisation decisions require professional medical assessment. Never start, change, or stop these medications without consulting your prescribing physician.

Mechanism of Action

Amlodipine is a third-generation, long-acting dihydropyridine (DHP) calcium channel blocker with exceptionally high selectivity for L-type voltage-gated calcium channels in arterial vascular smooth muscle compared to cardiac myocytes. Unlike verapamil and diltiazem, amlodipine has minimal direct cardiac effects at therapeutic doses — its blood pressure-lowering effect is achieved through selective arterial vasodilation: blockade of L-type calcium channels in arteriolar smooth muscle reduces intracellular calcium, causing profound relaxation of resistance arterioles. This reduces systemic vascular resistance and lowers blood pressure without significant changes in heart rate, cardiac output, or AV conduction. Amlodipine’s anti-anginal effect combines peripheral arterial dilation (reducing cardiac afterload and myocardial oxygen demand) with direct coronary vasodilation (improving myocardial oxygen supply). Two pharmacokinetic properties make amlodipine uniquely valuable among CCBs: (1) An exceptionally long half-life of 35–50 hours enabling reliable once-daily dosing with minimal day-to-day plasma level variation; (2) Extremely slow receptor binding on-rate and very slow off-rate (‘slow channel binding kinetics’) that eliminates first-dose hypotension, produces a gradual onset preventing reflex tachycardia, and provides exceptionally smooth, sustained blood pressure control. S-Amlodipine (levamlodipine) is the pharmacologically active (S-) enantiomer — providing equivalent antihypertensive effect at half the dose of racemic amlodipine, with reduced ankle oedema due to lower drug exposure.

Metoprolol succinate is a highly cardioselective beta-1 adrenoceptor antagonist with approximately 75:1 beta-1:beta-2 selectivity, available as an extended-release once-daily formulation via the OROS (osmotic release oral system) technology. Metoprolol succinate XL/ER provides controlled, consistent drug release over 24 hours — achieving near-linear plasma concentrations with minimal peak-to-trough fluctuation compared to metoprolol tartrate (immediate-release). This pharmacokinetic profile translates to more consistent heart rate reduction, better tolerability, and once-daily dosing convenience. The landmark MERIT-HF trial demonstrated metoprolol succinate CR/XL 200mg/day reduces all-cause mortality in HFrEF by 34% compared to placebo — one of the pivotal trials establishing guideline-directed medical therapy for heart failure. S-Metoprolol (the active enantiomer, Starcad Beta) provides equivalent clinical benefit at half the standard dose with potentially improved tolerability due to reduced drug exposure.

Clinical Indications

Revelol AM 25/5mg Tablet (Amlodipine/Metoprolol Succinate) is indicated for:

• Primary indication: hypertension — particularly where both vasodilatory CCB and rate-slowing/cardiac-protecting beta-blockade are clinically indicated; stable angina with hypertension
• Confirmed diagnosis required: A qualified healthcare professional must confirm the diagnosis and determine appropriateness of therapy.

Dosage and Administration

One tablet once daily. The beta-blocker component counters the reflex tachycardia occasionally produced by amlodipine’s vasodilation, making this a pharmacologically rational combination.

Who Should Use Revelol AM 25/5

Revelol AM 25/5 is appropriate for patients confirmed by a qualified healthcare professional to have the conditions listed in the indications section, in whom this specific formulation is clinically appropriate following benefit-risk assessment with no absolute contraindications.

Contraindications

Severe bradycardia. High-degree AV block without pacemaker. Decompensated acute heart failure. Cardiogenic shock. Severe asthma/bronchospasm (non-selective agents absolute contraindication; cardioselective agents use with extreme caution even in mild asthma). Hypersensitivity. Severe aortic stenosis.

Drug Interactions

Standard interactions of both drug classes — see individual monographs. Verapamil/diltiazem with beta-blocker component: additive AV block risk.

A complete medication review is essential before initiating Revelol AM 25/5. Cardiovascular and hormonal drugs have numerous clinically significant interactions that can be dangerous if unidentified. Patients must inform all healthcare providers of their complete medication list.

Adverse Effects

Common: Peripheral oedema (ankle swelling), headache, flushing. Uncommon: Palpitations, dizziness, nausea. Rare: Gingival hyperplasia with long-term use.

Common: Fatigue, bradycardia, cold extremities, and sleep disturbance. Uncommon: Bronchoconstriction (less with cardioselective agents; still a risk in severe asthma), sexual dysfunction, depression, dizziness. Rare: Severe bradyarrhythmia, AV block, acute heart failure decompensation.

Combination benefit: beta-blocker component significantly reduces the ankle oedema produced by amlodipine through venoconstriction (counteracting arteriolar dilation-driven oedema).

Special Population Considerations

The amlodipine + beta-blocker combination is widely used because these two drug classes have complementary mechanisms and their side effects partially counteract each other — beta-blockers reduce amlodipine’s reflex tachycardia and ankle oedema, while amlodipine’s vasodilation counteracts beta-blocker-induced peripheral constriction.

Storage

Store Revelol AM 25/5 at room temperature (15–25°C) away from direct sunlight, heat, and moisture. Keep in original packaging. Maintain out of reach of children. Do not use beyond expiry date.

Frequently Asked Questions

Q: How should I store this medication?
A: Store at room temperature (15–25°C), away from direct sunlight, heat, and moisture. Keep in original packaging out of reach of children. Do not use after the expiry date.

Q: What should I do if I miss a dose?
A: Take the missed dose as soon as you remember unless it is nearly time for the next dose. Never double-dose. Do not stop cardiovascular medications abruptly without medical advice.

Q: Why combine amlodipine with a beta-blocker?
A: Amlodipine causes vasodilation that can trigger mild reflex tachycardia in some patients. Beta-blockers block this reflex tachycardia and provide additional cardioprotection. Both drug classes lower blood pressure through complementary mechanisms — CCB vasodilation and beta-blocker reduced cardiac output/renin suppression. The combination also reduces amlodipine-associated ankle oedema as beta-blocker venoconstriction counteracts the CCB’s arteriolar dilation-driven increase in capillary pressure.

Evidence Base and Clinical Guidelines

The active ingredient in Revelol AM 25/5 has been evaluated in landmark randomised controlled trials and is supported by international cardiovascular guidelines from the ESC, ACC/AHA, NICE, and national specialist bodies. Evidence-based cardiovascular pharmacotherapy has transformed outcomes for hypertension, angina, heart failure, and arrhythmia management. GMP-compliant manufacturing ensures consistent product quality and safety.

Cardiovascular Disease Management Context

Pharmacological therapy delivers best outcomes when integrated with lifestyle modification: Mediterranean-style diet, regular aerobic physical activity (150 minutes/week moderate intensity), smoking cessation, alcohol moderation, and sodium restriction for hypertension and heart failure. The combination of optimal pharmacotherapy and sustained lifestyle change produces cardiovascular risk reduction far exceeding either approach alone. Regular follow-up monitoring — blood pressure recording, ECG, renal function and electrolytes — is essential to optimise therapy and detect adverse effects early.

Fixed-dose combination antihypertensive tablets — such as many products in this range — significantly improve treatment adherence, which is the single most common reason for inadequate blood pressure control in treated hypertensive patients. Multiple studies demonstrate that every 10mmHg sustained reduction in systolic blood pressure reduces major cardiovascular event risk by approximately 20%, providing strong motivation for achieving and maintaining blood pressure targets.

Patient Counselling Key Points

• Do not stop abruptly: Beta-blockers, antianginals, and antihypertensives must be withdrawn gradually under medical supervision — abrupt withdrawal risks angina rebound, hypertensive crisis, or cardiac decompensation.
• Monitor blood pressure: Home blood pressure monitoring at the same time daily provides valuable data for dose optimisation — target below 130/80 mmHg in most guidelines for hypertensive patients with cardiovascular disease.
• Carry medication list: All patients on cardiovascular medications should carry a complete medication list for surgical, dental, and emergency care encounters where drug interactions are critical.

Cardiovascular Disease Management Principles

Cardiovascular disease (CVD) remains the leading cause of mortality worldwide, responsible for approximately 18 million deaths annually. Hypertension alone affects 1.28 billion adults globally — yet only 21% achieve adequate blood pressure control. The gap between evidence-based pharmacotherapy and real-world practice represents the greatest opportunity for cardiovascular risk reduction: consistently achieving guideline-recommended blood pressure targets, lipid goals, and cardiac function optimisation through appropriate, adherent pharmacotherapy has the potential to prevent hundreds of thousands of cardiovascular events annually.

Modern antihypertensive management has evolved substantially — from the early era of single-drug therapy to the current paradigm of early combination therapy targeting multiple pathophysiological mechanisms simultaneously. Multiple large randomised controlled trials and their meta-analyses demonstrate that combination antihypertensive therapy achieves blood pressure targets more effectively than monotherapy titration, with better cardiovascular outcomes. The ACCOMPLISH trial demonstrated CCB+ACE-I superiority over diuretic+ACE-I for cardiovascular events; ONTARGET established ARB equivalence to ACE-I; MERIT-HF, COPERNICUS, CIBIS-II, and EMPHASIS-HF established beta-blocker and MRA therapy for HFrEF. This robust evidence base is incorporated into ESC, ACC/AHA, and NICE guidelines that inform contemporary prescribing decisions.

Fixed-Dose Combination Therapy: Adherence and Outcomes

Non-adherence to antihypertensive therapy is the single most common reason for inadequate blood pressure control in treated patients — affecting approximately 50% of patients within the first year of treatment. Fixed-dose combinations (FDCs) address this critical problem by reducing pill burden, simplifying regimens, and improving convenience. Multiple meta-analyses confirm that FDC antihypertensive therapy significantly improves adherence compared to equivalent separate tablets, translating to better blood pressure control and improved cardiovascular outcomes.

The products in this range — spanning beta-blockers with CCBs, ARBs with CCBs and diuretics, triple combinations, and specialised anti-anginal agents — reflect contemporary evidence-based combination therapy strategies. Selection among these options requires individual patient assessment integrating blood pressure severity, comorbidities (diabetes, CKD, heart failure, AF), tolerability factors, and concurrent medications.

Evidence Base and Quality Standards

The active ingredients in this product have been evaluated in landmark randomised controlled trials forming the foundation of evidence-based cardiovascular medicine. Major international guidelines from the European Society of Cardiology (ESC/ESH), American College of Cardiology/American Heart Association (ACC/AHA), and National Institute for Health and Care Excellence (NICE) support their use in evidence-based treatment algorithms. GMP-compliant manufacturing ensures consistent product quality, identity, strength, and safety across all manufactured batches. Patients should obtain prescription cardiovascular medications only through licensed pharmacies with valid prescriptions to ensure receipt of authentic, quality-assured products.

Blood Pressure Targets and Monitoring

Current major cardiovascular guidelines (ESC/ESH 2023, ACC/AHA 2017) recommend the following blood pressure targets for hypertensive patients: general adult population with uncomplicated hypertension, target below 130/80 mmHg; patients aged ≥65 years, target 130–139/70–79 mmHg (avoiding over-treatment which may paradoxically increase risk through J-curve phenomena); patients with CKD and proteinuria, target below 130/80 mmHg; patients with coronary artery disease and stable angina, target 130/80 mmHg or lower; patients with diabetes mellitus, target below 130/80 mmHg.

Home blood pressure monitoring (HBPM) and 24-hour ambulatory BP monitoring (ABPM) are recommended over office BP measurements alone for treatment decisions — office measurements overestimate true BP (white coat hypertension) in approximately 15–30% of patients and underestimate it (masked hypertension) in others. ABPM or HBPM provides more accurate cardiovascular risk assessment and better treatment optimisation.

Patient Counselling Summary

Key points for all patients on antihypertensive and cardiovascular medications: Take medications at the same time daily for consistent drug levels. Never skip doses — cardiovascular medications require consistent daily use for their full protective benefit. Never stop medications abruptly — particularly beta-blockers (rebound angina/hypertension risk) and antianginal drugs. Monitor blood pressure at home at the same time each day in a relaxed, seated position after 5 minutes rest. Report side effects promptly — many can be managed with dose adjustment or substitution rather than discontinuation. Maintain lifestyle modifications: salt restriction (below 6g/day), DASH or Mediterranean diet, regular moderate-intensity aerobic exercise (150 minutes/week), smoking cessation, and alcohol moderation. Attend all scheduled follow-up appointments for blood pressure recording, ECG, and biochemical monitoring as indicated.

Important Medical Disclaimer

This product information guide is provided for general educational purposes only, prepared in accordance with YMYL (Your Money Your Life) content standards. All information draws on regulatory prescribing information, peer-reviewed pharmacological literature, and established clinical guidelines. It does not replace professional medical advice from a qualified physician, cardiologist, endocrinologist, gynaecologist, or pharmacist. Drug therapy decisions must be individualised. Self-diagnosis and self-treatment of cardiovascular, hormonal, and parasitic conditions can be dangerous. Always consult a qualified healthcare professional before starting, changing, or stopping any medication.